首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1489215

全球多种癌症早期检测市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

Global Multi Cancer Early Detection Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年05月01日 | 出版商:

Value Market Research | 英文 122 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

预计到2032年，全球多癌症早期检测市场的市场规模将从2023年的9.8956亿美元达到近41.3801亿美元，2024-2032年研究期间的复合年增长率为17.23%。

多种癌症早期检测涉及使用先进的诊断技术同时或依序对个体进行多种类型的癌症筛检。与传统的单一癌症筛检测试不同，多癌症检测方法旨在在治疗更有效的早期阶段识别更广泛的癌症类型。这些方法可能包括血液测试、成像技术和检测与各种癌症相关的特定生物标记的分子测定。透过更早发现癌症，多种癌症筛检可以针对个别患者采取及时介入和治疗策略，从而提高存活率并降低癌症相关死亡率。

市场动态

全球癌症盛行率的不断上升以及晚期诊断负担的日益增加，凸显了对更有效的筛检方法的迫切需要，这些方法能够在更早期、更可治疗的阶段检测出多种癌症类型。此外，基因组和蛋白质组学技术的进步，包括下一代定序（NGS）、液体活检和肿瘤标记分析，使得高灵敏度和特异性的多种癌症早期检测测试的开发成为可能，这些测试可以检测循环肿瘤DNA（ctDNA）、蛋白质和其他指示血液样本中各种癌症类型的生物标记。此外，越来越多地采用人工智慧和机器学习演算法进行资料分析和解释，提高了多种癌症筛检测试的准确性和可靠性，减少了误报，并改善了诊断结果。此外，医疗保健提供者、政策制定者和公众对早期癌症检测重要性的认识不断提高，加上筛检测试报销选项的可用性，正在推动对多种癌症早期检测解决方案的需求，塑造市场的未来。然而，大规模实施多种癌症筛检计画的复杂性和成本，以及伦理考量和病患隐私问题，可能会在未来几年挑战多种癌症早期检测市场的成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球多癌症早期检测市场的各个细分市场进行了包容性评估。多种癌症早期检测产业的成长和趋势为这项研究提供了整体方法。

市场区隔

多癌症早期检测市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按类型

液体活检
基因组 & LDT 其他

按最终用途

医院
诊断实验室
其他的

区域分析

本节涵盖区域展望，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲多癌症早期检测市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。多重癌症早期检测市场的主要参与者包括Illumina Inc. (GRAIL LLC)、Exact Sciences Corp.、Foundation Medicine Inc.、AnchorDx、Guardant Health、燃石生物科技有限公司、Genecast、北京莱曼君泰国际医疗技术发展有限公司.、Freenome Holdings Inc.、Elypta AB。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 8 章：多种癌症早期检测公司的竞争格局

多种癌症早期检测市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 9 章：公司简介

顶级公司市占率分析
市场集中度
Illumina Inc. (GRAIL LLC)

公司简介
公司收入
产品
最近的发展

Exact Sciences Corp.

公司简介
公司收入
产品
最近的发展

Foundation Medicine Inc.

公司简介
公司收入
产品
最近的发展

AnchorDx

公司简介
公司收入
产品
最近的发展

Guardant Health

公司简介
公司收入
产品
最近的发展

Burning Rock Biotech Ltd.

公司简介
公司收入
产品
最近的发展

GENECAST

公司简介
公司收入
产品
最近的发展

Beijing Lyman Juntai International Medical Technology Development Co.

公司简介
公司收入
产品
最近的发展

Freenome Holdings Inc.

公司简介
公司收入
产品
最近的发展

Elypta AB

公司简介
公司收入
产品
最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112114514

The global demand for Multi Cancer Early Detection Market is presumed to reach the market size of nearly USD 4138.01 Million by 2032 from USD 989.56 Million in 2023 with a CAGR of 17.23% under the study period 2024-2032.

Multi cancer early detection involves screening individuals for multiple types of cancer simultaneously or sequentially using advanced diagnostic technologies. Unlike traditional single-cancer screening tests, multi-cancer detection methods aim to identify a broader range of cancer types at earlier stages when treatment is more effective. These approaches may include blood tests, imaging techniques, and molecular assays that detect specific biomarkers associated with various cancers. By detecting cancers earlier, multi-cancer screening can improve survival rates and reduce cancer-related mortality by enabling timely intervention and treatment strategies tailored to individual patients.

MARKET DYNAMICS

The spurring prevalence of cancer worldwide and the growing burden of late-stage diagnoses highlight the urgent need for more effective screening methods capable of detecting multiple cancer types at earlier, more treatable stages. Additionally, the advancements in genomic and proteomic technologies, including next-generation sequencing (NGS), liquid biopsy, and tumor marker analysis, have enabled the development of highly sensitive and specific multi cancer early detection tests that can detect circulating tumor DNA (ctDNA), proteins, and other biomarkers indicative of various cancer types in blood samples. Furthermore, the rising adoption of artificial intelligence & machine learning algorithms for data analysis and interpretation enhances the accuracy and reliability of multi-cancer screening tests, reduces false positives, and improves diagnostic outcomes. Moreover, the spurring awareness of the significance of early cancer detection among healthcare providers, policymakers, and the general public, coupled with the availability of reimbursement options for screening tests, is driving demand for multi-cancer early detection solutions, shaping the market's future. However, the complexity and cost of implementing multi-cancer screening programs on a large scale, along with ethical considerations and patient privacy concerns, may challenge the multi cancer early detection market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Multi Cancer Early Detection. The growth and trends of Multi Cancer Early Detection industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Multi Cancer Early Detection market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Liquid Biopsy
Gene Panel & LDT Others

By End-use

Hospitals
Diagnostic Laboratories
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Multi Cancer Early Detection market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Multi Cancer Early Detection market include Illumina Inc. (GRAIL LLC), Exact Sciences Corp., Foundation Medicine Inc., AnchorDx, Guardant Health, Burning Rock Biotech Ltd., Genecast, Beijing Lyman Juntai International Medical Technology Development Co., Freenome Holdings Inc., Elypta AB. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. MULTI CANCER EARLY DETECTION - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By End-use
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL MULTI CANCER EARLY DETECTION MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data
5.3. Analysis By Type
5.4. Liquid Biopsy Historic and Forecast Sales By Regions
5.5. Gene Panel & LDT Others Historic and Forecast Sales By Regions

6. GLOBAL MULTI CANCER EARLY DETECTION MARKET ANALYSIS BY END-USE

6.1. Overview By End-use
6.2. Historical and Forecast Data
6.3. Analysis By End-use
6.4. Hospitals Historic and Forecast Sales By Regions
6.5. Diagnostic Laboratories Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL MULTI CANCER EARLY DETECTION MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE MULTI CANCER EARLY DETECTION COMPANIES

8.1. Multi Cancer Early Detection Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF MULTI CANCER EARLY DETECTION INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Illumina Inc. (GRAIL LLC)
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Exact Sciences Corp.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Foundation Medicine Inc.
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. AnchorDx
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Guardant Health
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Burning Rock Biotech Ltd.
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. GENECAST
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Beijing Lyman Juntai International Medical Technology Development Co.
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Freenome Holdings Inc.
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Elypta AB
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments